Loading...
Please wait, while we are loading the content...
Similar Documents
Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice
| Content Provider | Scilit |
|---|---|
| Author | Joseph, Richard W. Chatta, Gurkamal Vaishampayan, Ulka |
| Copyright Year | 2017 |
| Description | Journal: Urologic oncology Nivolumab is an important new therapy option for patients with advanced renal cell carcinoma, and has a different mechanism of action compared with vascular endothelial growth factor -targeted therapies. It is a programmed death 1 immune checkpoint inhibitor antibody with response patterns, efficacy, and safety profiles that differ from those of conventional antiangiogenic or mammalian target of rapamycin inhibition therapy. This commentary discusses and evaluates the clinical experience with nivolumab from the available literature and presents practical considerations for the use of nivolumab immunotherapy in aRCC to optimize clinical management. |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6863156/pdf |
| Ending Page | 148 |
| Page Count | 7 |
| Starting Page | 142 |
| ISSN | 10781439 |
| DOI | 10.1016/j.urolonc.2017.01.017 |
| Journal | Urologic oncology |
| Issue Number | 4 |
| Volume Number | 35 |
| Language | English |
| Publisher | Elsevier BV |
| Publisher Date | 2017-04-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: Urologic oncology Urology and Nephrology Advanced Renal Cell Carcinoma Immune Checkpoint Inhibitor Immunotherapy Agents Pd-1 Inhibitor Second-line Therapy |
| Content Type | Text |
| Resource Type | Article |
| Subject | Urology Oncology |
